Company intelligence / Profile preview

Equashield

Ownership: Private
Employees: ~460
Development stage: Commercial

Overview

Equashield’s CSTDs and automated compounding solutions are FDA-cleared and CE-marked. Their devices are clinically validated to prevent microbial ingress for up to seven days, reduce healthcare worker exposure to hazardous drugs, improve safety in pharmacy/nursing workflows, and streamline sterile manufacturing for cell/gene therapies. The company’s products are the most used CSTD in the US market.

Therapeutic areas: OncologyImmunology
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Equashield.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Equashield.

Explore the full profile